Treating osteoporosis by targeting parathyroid hormone to bone

T. Ponnapakkam, R. Katikaneni, J. Sakon, R. Stratford, R. C. Gensure

Research output: Contribution to journalShort survey

24 Scopus citations

Abstract

Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2% with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalDrug Discovery Today
Volume19
Issue number3
DOIs
Publication statusPublished - Mar 2014

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Ponnapakkam, T., Katikaneni, R., Sakon, J., Stratford, R., & Gensure, R. C. (2014). Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discovery Today, 19(3), 204-208. https://doi.org/10.1016/j.drudis.2013.07.015